Geoffrey Oxnard, MD
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology

MD, University of Chicago
AB, Harvard University



Geoffrey Oxnard is a thoracic oncologist at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. The aims of Dr. Oxnard’s research are to develop clinical applications for cancer genotyping technologies to advance precision cancer care.

Dr. Oxnard has published extensively on sensitivity and resistance to EGFR kinase inhibitors in lung cancer with a focus on the clinical biology of the EGFR T790M mutation. More recently his research has focused on genomic analysis of plasma cell-free DNA as a diagnostic to assist in treatment planning, response monitoring, and cancer detection.

Dr. Oxnard received his BA in chemistry from Harvard University and his MD from the University of Chicago-Pritzker School of Medicine. He served his residency in internal medicine at Massachusetts General Hospital and completed his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center, joining the Dana-Farber faculty in 2011.

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Andrews HS, Zariffa N, Nishimura KK, Choi SH, Deng S, Eisele M, Espenschied CR, Goren EM, Guha M, Hong S, Juraeva D, Krämer N, Liu L, Martini JF, McKelvey BA, Oxnard GR, Pestano GA, Poole L, Rosenthal A, Szpurka AM, Vega DM, Ward C, Wijayawardana SR, Hoering A, Stewart MD, Allen JD. ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials. Clin Cancer Res. 2025 Apr 22; OF1-OF11. PMID: 40261185
     
  2. Fujisawa T, Nakamura Y, Bando H, Morizane C, Ikeda M, Nonomura N, Matsubara N, Iwata H, Naito Y, Okano S, Aoki D, Harano K, Yamazaki N, Namikawa K, Ueno M, Kadowaki S, Oki E, Kato K, Komatsu Y, Satoh T, Esaki T, Denda T, Hamaguchi T, Yamazaki K, Matsuhashi N, Yasui H, Satake H, Nishina T, Takahashi N, Goto M, Sunakawa Y, Kato T, Otsuka T, Abutani H, Tukachinsky H, Lee JK, Oxnard GR, Kuramoto N, Horasawa S, Sakamoto Y, Taniguchi H, Yoshino T. Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study. JCO Precis Oncol. 2025 Apr; 9:e2400283. PMID: 40209142
     
  3. Gautschi O, Park K, Solomon BJ, Tomasini P, Loong HH, De Braud F, Goto K, Peterson P, Barker S, Liming K, Oxnard GR, Frimodt-Moller B, Drilon A. Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2025 May 20; 43(15):1758-1764. PMID: 39983053
     
  4. Gandara DR, Agarwal N, Gupta S, Klempner SJ, Andrews MC, Mahipal A, Subbiah V, Eskander RN, Carbone DP, Riess JW, Sammons S, Snider J, Bouzit L, Cho-Phan C, Price M, Li G, Quintanilha JCF, Huang RSP, Ross JS, Fabrizio D, Oxnard GR, Graf RP. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J Immunother Cancer. 2025 Feb 06; 13(2). PMID: 39915003; PMCID: PMC11815411; DOI: 10.1136/jitc-2024-010311;
     
  5. Paweletz CP, Urvalek A, Ha M, Garg K, Bence Lin A, Szpurka AM, Sireci A, Oxnard GR, Janne PA. Round-robin comparison of RET rearrangement detection in ctDNA: A novel method for limited clinical samples. Clin Cancer Res. 2025 Jan 31. PMID: 39887260
     
  6. Mack PC, Keller-Evans RB, Li G, Lofgren KT, Schrock AB, Trabucco SE, Allen JM, Tolba K, Oxnard GR, Huang RSP. Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC. Oncologist. 2024 Aug 05; 29(8):e984-e996. PMID: 38401173; PMCID: PMC11299949; DOI: 10.1093/oncolo/oyae028;
     
  7. Rolfo CD, Madison RW, Pasquina LW, Brown DW, Huang Y, Hughes JD, Graf RP, Oxnard GR, Husain H. Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. Clin Cancer Res. 2024 Jun 03; 30(11):2452-2460. PMID: 38526394; PMCID: PMC11145175; DOI: 10.1158/1078-0432.CCR-23-3321;
     
  8. Andrews MC, Li G, Graf RP, Fisher VA, Mitchell J, Aboosaiedi A, O'Rourke H, Shackleton M, Iddawela M, Oxnard GR, Huang RSP. Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma. JCO Precis Oncol. 2024 Jun; 8:e2300640. PMID: 38848517; PMCID: PMC11371113; DOI: 10.1200/PO.23.00640;
     
  9. Yorio J, Lofgren KT, Lee JK, Tolba K, Oxnard GR, Schrock AB, Huang RSP, Brisbin L. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2024 Mar; 8:e2300292. PMID: 38452312; PMCID: PMC10939592; DOI: 10.1200/PO.23.00292;
     
  10. Mata DA, Lee JK, Shanmugam V, Marcus CB, Schrock AB, Williams EA, Ritterhouse LL, Hickman RA, Janovitz T, Patel NR, Kroger BR, Ross JS, Mirza KM, Oxnard GR, Vergilio JA, Elvin JA, Benhamida JK, Decker B, Xu ML. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology. 2024 Jun; 84(7):1224-1237. PMID: 38422618
     
Showing 10 of 209 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 209 publications over 22 distinct years, with a maximum of 28 publications in 2022

YearPublications
20041
20052
20061
20072
20081
20091
20104
20118
20126
20139
20145
201517
201614
20178
201816
20199
202022
202118
202228
202324
20248
20255

Note: X.com has changed/limited the ability to embed tweets directly in external sites and we are investigating ways to restore that functionality in BU Profiles. In the meantime we are displaying a link to your x.com profile in the Websites section above.
Contact for Mentoring:

820 Harrison Ave Boston MA
Google Map


Oxnard's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department